Huaren Pharmaceutical Co., Ltd. Class A

Huaren Pharmaceutical Co., Ltd. Class A

SSZSE:300110
2.53
CNY
-0.04
(-1.56%)
-0.41EPS
3.75BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.79
0.76
0.96
1.18
1.33
1.2
1.25
1.11
1.32
1.37
1.38
1.14
1.12
1.03
Basic EPS, GAAP
0.11
0.05
0.02
0.02
0.04
0.03
0.04
0.08
0.11
0.15
0.16
-1.16
-0.39
-0.41
Free Cash Flow per Basic Share
-0.17
-0.16
-0.12
0.01
0.13
0.18
0.24
-0.06
-0.51
0.15
0.22
0.25
0.29
- -
Dividend per Share
0.02
0.07
0.08
0.05
0.05
0.05
0.05
0.02
0.06
0.08
0.07
0.07
0.04
0.03
Book Value per Share
1.26
1.28
1.26
1.29
1.31
1.83
1.84
1.91
2.01
2.14
2.28
1.1
0.71
0.73
Tangible Book Value per Share
1.14
1.15
1.13
1.16
1.18
1.71
1.72
1.54
0.99
1.15
1.3
0.22
0.29
0.33
Basic Weighted Avg Shares
1,102
1,209
1,148
1,055
985
1,151
1,169
1,183
1,185
1,182
1,182
1,182
1,182
1,182
Sales/Revenue/Turnover
867
917
1,106
1,249
1,312
1,384
1,462
1,317
1,561
1,619
1,636
1,353
1,321
1,219
Operating Margin (%)
20.12
12.02
9.25
8.14
11.11
7.79
11.03
13.38
19.69
19.01
18.7
11.24
12.71
11.2
Depreciation Expense
86
97
115
123
123
116
116
113
135
150
127
118
108
- -
Net Income, GAAP
122
56
23
24
38
39
42
95
130
181
188
-1,368
-463
-491
Effective Tax Rate (%)
15.23
11.96
8.79
17.12
27.43
14
33
13.21
10.79
11.93
16.09
- -
- -
- -
Profit Margin (%)
14.01
6.13
2.07
1.92
2.86
2.8
2.88
7.19
8.35
11.16
11.49
-101.13
-35.03
-40.24
Working Capital
117
-57
-117
5
112
770
886
541
517
700
1,275
-362
-481
-190
LT Debt
15
7
30
29
63
42
25
- -
231
353
837
464
271
471
Total Equity
1,459
1,480
1,440
1,526
1,548
2,242
2,248
2,330
2,443
2,600
2,766
1,374
909
935
Return on Invested Capital (%)
6.55
2.58
0.87
1.11
1.92
1.53
1.9
4.1
3.98
4.06
4.32
- -
- -
- -
Return on Capital (%)
7.68
4.08
3.22
2.78
2.48
2.63
1.99
3.83
4.99
5.26
5.11
- -
- -
- -
Return on Common Equity (%)
8.85
3.82
1.57
1.65
2.54
2.12
1.94
4.27
5.63
7.38
7.2
-68.51
-43.29
-44.54

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
826
879
779
LT Borrowings
464
401
470
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,182
1,182
1,182
Market Capitalization
3,712
2,932
3,748

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,106
1,090
1,068
Cash, Cash Equivalents & STI
185
213
233
Accounts Receivable, Net
499
456
423
Inventories
246
240
235
Total Current Liabilities
1,349
1,361
1,257
Payables & Accruals
- -
- -
- -
ST Debt
826
879
779
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.03%
-13.3%
-33.83%
Free Cash Flow
147.26%
146.14%
14.64%
Net Income, GAAP
-61.55%
-162.67%
-66.17%
Sales/Revenue/Turnover
2.29%
0.74%
-2.34%
Total Cash Common Dividend
9.67%
36.96%
-46.18%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
407
365
302
280
1,353
2025
303
320
- -
345
1,321
2026
310
295
269
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.02
0.02
-1.24
-1.16
2025
0.01
0.02
- -
-0.44
-0.39
2026
0.01
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
0.03
0.01
0.07
2025
0.01
0.01
- -
- -
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Li Zhiyong
Full Time Employees
2,549
Sector
Health technology
Industry
Medical specialties
Address
No. 187, Zhuzhou Road Qingdao SD China 266101
IPO Date
Aug 25, 2010
Business
Huaren Pharmaceutical Co., Ltd. is a China-based pharmaceutical and health industry group established in May 1998 and headquartered in Qingdao, Shandong Province. The company integrates research and development, production, and sales, focusing on pharmaceutical preparations, active pharmaceutical ingredients (APIs), medical devices, and pharmaceutical packaging materials. Its core product portfolio includes small-volume injections, large-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, tablets, capsules, powders, granules, health products, and supporting drug packaging materials. The company operates five production bases located in Qingdao, Rizhao, Xiaogan, Pubei, and Hefei, with a total production capacity of approximately 950 million bags/bottles annually. Huaren Pharmaceutical's key therapeutic focuses include nephrology, respiratory diseases, psychotropic and narcotic drug treatments, fine anesthesia, and large-volume infusion preparations. It serves domestic and international markets including Europe, Southeast Asia, and the Middle East. Huaren Pharmaceutical is also a designated emergency reserve infusion manufacturer in Shandong Province. Recent major developments include the company's strategic emphasis on innovation and expanding its pharmaceutical health industry layout through independent research and collaborative innovation, continuing to increase R&D investment, and enriching its product lines. It underwent a shareholding restructure in 2019, with the management committee of Xi'an Qujiang New Area becoming the actual controller. The company actively responds to China's "Healthy China" strategy to grow into a comprehensive pharmaceutical and health group that integrates APIs, preparations, medical devices, and pharmaceutical packaging. In addition, Huaren Pharmaceutical and its wholly owned subsidiaries, including Guangxi Yuyuan Pharmaceutical Co., Ltd., continue expanding their operational footprint. The company keeps aligning with regulatory standards such as new GMP certifications across its production lines to maintain quality and compliance. Chairman Yang Xiaodong has recently increased his shareholdings, reflecting management confidence in the company's prospects. Overall, Huaren Pharmaceutical Co., Ltd. operates as a modern pharmaceutical group providing a broad spectrum of pharmaceutical products and medical devices with ongoing strategic investments in innovation, production capacity expansions, and market development across China and international regions.